Progress in the application of molecular imaging in psychiatric disorders-Reference-Cited by-同舟云学术

Progress in the application of molecular imaging in psychiatric disorders

Published:2023 Issue: Volume:3 Page:
ISSN:2634-4416
Container-title:Psychoradiology
language:en
Short-container-title:

Author:

Tan Jia¹²,Zhang Guangying³,Hao Jiaqi¹²,Cai Huawei⁴,Wu Dingping¹,Su Zhuoxiao¹,Liu Beibei¹,Wu Min¹²^ORCID

Affiliation:

1. Department of Radiology and Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University , Chengdu 610041 , China

2. Research Unit of Psychoradiology, Chinese Academy of Medical Sciences , Chengdu 610041 , China

3. Department of Radiology, Banan People's Hospital, Chongqing Medical University , Chongqing 400037 , China

4. Department of Nuclear Medicine and Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University , Chengdu 610041 , China

Abstract

Abstract Psychiatric disorders have always attracted a lot of attention from researchers due to the difficulties in their diagnoses and treatments. Molecular imaging, as an emerging technology, has played an important role in the researchers of various diseases. In recent years, molecular imaging techniques including magnetic resonance spectroscopy, nuclear medicine imaging, and fluorescence imaging have been widely used in the study of psychiatric disorders. This review will briefly summarize the progression of molecular imaging in psychiatric disorders.

Funder

Stanford University

Sichuan Foundation for Distinguished Young Scholars

Sichuan University

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

https://academic.oup.com/psyrad/advance-article-pdf/doi/10.1093/psyrad/kkad020/51967206/kkad020.pdf

Reference111 articles.

1. Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis;Bragulat;Psychiatry Res,2007

2. Proton magnetic resonance spectroscopy and illness stage in schizophrenia—a systematic review and meta-analysis;Brugger;Biol Psychiatry,2011

3. Changes of dopamine transporter availability in depressed patients with and without anhedonia: a 123I-N-ω-fluoropropyl-carbomethoxy-3β- (4-Iodophenyl)tropane SPECT study;Camardese;Neuropsychobiology,2014

4. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography;Cannon;Biol Psychiatry,2006

5. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112;Cannon;Neuropsychopharmacology,2009